Full Press Release Details
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022.
IMMP
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
Key Takeaway: Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
Price reaction · baseline $2.1 (2022-11-08 close) · hit after-hours · 4 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-7.6%
day 1
-0.5%
day 3
+4.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)